The Draft Regulation of the Minister of Health Amending the Regulation on the National Cancer Registry has been submitted for consultation.
Big changes in the National Cancer Registry
Published March 23, 2023 10:45
The draft regulation proposes to amend the scope of data collected by the registry.
It is assumed that the amendment to the regulation will allow the following purposes to continue in an expanded scope:
1) monitoring the demand for health care services;
2) monitoring the health status of recipients of cancer services;
3) ongoing analysis of the collected data on the incidence of malignant neoplasms;
4) creation of a homogeneous and internationally comparable data set on malignant neoplasms;
5) evaluation of the effectiveness of the diagnosis and treatment of malignant neoplasms by analyzing survival;
6) tracking changes over time and space in the incidence of malignant neoplasms;
7) providing a basis for evaluating the effectiveness of prevention programs;
8) providing a basis for determining the needs for the development of oncological treatment.
Regarding oncohematological cancers, the recommended solution is to collect data on hematological cancers.
The e-KRN+ project, under which the registry will operate, will offer integration of the Integrated Hospital Information Systems, hereinafter referred to as "HIS", with the registry system. The project will integrate 4 systems (3 departments of NIO-PIB, and the Institute of Hematology and Transfusiology. Integrating the HIS with the registry system removes the entity's obligation to transmit data in any other way. The second way to submit data is through a dedicated application, which is built with smart forms that adapt to the diagnosis being registered.
The current registry collects data on more than a hundred cancers, which by definition limits the detail of the data collected. The registry will also include hematological cancers in the ICD-10 C81-C96 and D45-D47 ranges.
The proposed changes to the registry are being introduced to: monitor the health status of recipients of diseases of lymphoid tissue, hematopoietic system and related tissues according to the therapies used, monitor the effectiveness and quality of treatment of hematooncological diseases.
Thanks to the changes introduced in the registry, it will be possible to assess risk factors for regional variation in morbidity, mortality, or survival of patients with oncohematological diseases. In addition, the registry will allow the development of treatment standards and their evaluation, as well as the identification of the number of patients requiring modern therapies.
It is assumed that the implementation of the registry changes will allow:
1) creation of a unified system for registering new cases of cancer of lymphatic and hematopoietic tissue (according to the International Statistical Classification of Diseases and Health Problems ICD-10: C81-C96, D45-D47);
2) preparation of the basis for population-based epidemiological studies that enable reliable analyses of the incidence and trends of the above cancers in real time;
3) assessment of the incidence of individual cancers of lymphoid tissue, blood system and related tissues;
4) monitoring of the health status of recipients of diseases of lymphoid tissue, blood system and related tissues depending on the therapy used;
5) monitoring of the effectiveness and quality of treatment of oncohematological diseases depending on the therapy used, as well as the patient's condition, the stage of the tumor and the treatment used;
6) recording of the distant results and sequelae of treatment depending on the therapy used;
7) systematic publication of reports based on the data collected in the registry.
Project: TU
Source: RCL
